A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate
Wittman, Brenda, Horan, John, Baxter, Joanna, Goldberg, John, Felgar, Raymond, Baylor, Erin, Cromwell, Bean, Cross, Nicholas and Bennett, John M. (2004) A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Leukemia Research, 28, (Supplement 1), 65-69. (doi:10.1016/j.leukres.2003.10.011).
Full text not available from this repository.
Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RJ Pediatrics > RJ101 Child Health. Child health services
|Divisions:||University Structure - Pre August 2011 > School of Medicine
|Date Deposited:||19 Nov 2008|
|Last Modified:||06 Aug 2015 02:49|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)